08:37 AM EDT, 06/03/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) and Pfizer ( PFE ) said Saturday that a Phase 3 trial assessing the experimental drug Adcetris in combination with chemotherapy to treat patients with Hodgkin lymphoma, a type of blood cancer, achieved its co-primary endpoints at a preplanned three-year analysis.

The study group demonstrated "superior" progression-free survival and "improved" tolerability versus the current standard of care regimen, the companies said, adding that the combination treatment led to a "significant reduction" in treatment-related morbidity and "clinically meaningful reductions" in adverse events.

Takeda Pharmaceutical ( TAK ) will deal with submitting potential regulatory filings based on the study outside of the US and Canada, while Pfizer ( PFE ) retains commercialization rights within these regions, the companies said. Takeda retains commercialization rights for Adcetris in the rest of the world, they added.

Price: 13.39, Change: +0.04, Percent Change: +0.30